Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04537637
Status:
COMPLETED
Last Update Posted:
2024-01-10
First Post:
2020-08-28
Brief Title:
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark as Part of Local Clinical Practice
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
A Multi-centre Prospective Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Denmark
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PIONEER REAL
Brief Summary:
The purpose of the study is to collect information on how Rybelsus works in people with type 2 diabetes and to see if Rybelsus can lower their blood sugar levels Participants will get Rybelsus as prescribed to them by the study doctor The study will last for about 8-10 months Participants will be asked to complete a questionnaire about how they take their Rybelsus tablets Participants will complete this questionnaire during their normally scheduled visit with the study doctor Participants will be asked to complete some questionnaires about their diabetes treatment Participants will complete these during their normally scheduled visits with the study doctor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1240-4198 | OTHER | World Health Organization WHO | None |